Core One Labs' Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment - GlobeNewswire

Submitted by Anonymous (not verified) on Wed, 07/21/2021 - 07:00

Core One Labs' Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment  GlobeNewswire